Adimab Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
135
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
Adimab General Information
Description
Developer of yeast-based human antibody discovery and engineering technologies designed to develop therapeutic antibodies. The company specializes in antibody discovery, affinity maturation, and production using yeast-based platforms, enabling biopharmaceutical companies to develop therapeutic candidates for cancer, autoimmune disorders, and infectious diseases.
Contact Information
Website
www.adimab.comCorporate Office
- 7 Lucent Drive
- Lebanon, NH 03766
- United States
Corporate Office
- 7 Lucent Drive
- Lebanon, NH 03766
- United States
Adimab Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | 01-Apr-2026 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 29-Dec-2020 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 01-Feb-2015 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series F) | 16-Apr-2012 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series E) | 29-Nov-2010 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series D) | 01-Oct-2009 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 20-Nov-2008 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 25-Mar-2008 | $3.18M | $9.5M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 20-Jul-2007 | $6.32M | $6.32M | Completed | Startup |
Adimab Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A2 | 1,574,133 | $0.001000 | $3.76 | $3.76 | 1x | $3.76 | 22.67% | |
| Series A1 | 300,000 | $0.001000 | $1.33 | $1.33 | 1x | $1.33 | 4.32% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Adimab Comparisons
Industry
Financing
Details
Adimab Competitors (73)
One of Adimab’s 73 competitors is Light Chain Bioscience, a Formerly PE-Backed company based in Geneva, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland | ||||
| Dren Bio | Venture Capital-Backed | San Carlos, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| XBiotech | Corporation | Austin, TX |
Adimab Patents
Adimab Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260132207-A1 | Activin type 2 receptor binding proteins and uses thereof | Pending | 31-Jul-2025 | ||
| WO-2026226938-A1 | Anti-gdf-15 antibodies and uses thereof | Pending | 24-Apr-2025 | ||
| WO-2026006458-A1 | Anti-cd3 antibodies and compositions and methods related thereto | Pending | 25-Jun-2024 | ||
| WO-2026006458-A9 | Anti-cd3 antibodies and compositions and methods related thereto | Pending | 25-Jun-2024 | ||
| WO-2025184137-A1 | Influenza antibodies and methods of use thereof | Pending | 27-Feb-2024 | C07K16/108 |
Adimab Signals
Adimab Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Apricot Capital (Shanghai) | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Lux Capital | Venture Capital | Minority | ||
| Premji Invest (US) | Growth/Expansion | Minority | ||
| Saints Capital | Secondary Buyer | Minority |
Adimab Investments & Acquisitions (3)
Adimab’s most recent deal was a Later Stage VC with Invivyd for . The deal was made on 19-Apr-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Invivyd | 19-Apr-2021 | Later Stage VC | Drug Discovery | ||
| Invivyd | 10-Nov-2020 | Early Stage VC | Drug Discovery | ||
| GenetaStix | 26-Jul-2007 | Merger/Acquisition | Biotechnology |
Adimab FAQs
-
When was Adimab founded?
Adimab was founded in 2007.
-
Where is Adimab headquartered?
Adimab is headquartered in Lebanon, NH.
-
What is the size of Adimab?
Adimab has 135 total employees.
-
What industry is Adimab in?
Adimab’s primary industry is Drug Discovery.
-
Is Adimab a private or public company?
Adimab is a Private company.
-
What is Adimab’s current revenue?
The current revenue for Adimab is .
-
How much funding has Adimab raised over time?
Adimab has raised $143M.
-
Who are Adimab’s investors?
Apricot Capital (Shanghai), , Lux Capital, Premji Invest (US), and Saints Capital are 5 of 7 investors who have invested in Adimab.
-
Who are Adimab’s competitors?
Light Chain Bioscience, Dren Bio, CytomX Therapeutics, Sarepta Therapeutics, and XBiotech are some of the 73 competitors of Adimab.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process